This study is evaluating a new investigational vaccine designed to help protect against three respiratory viruses that commonly affect older adults: respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3).
These viruses are associated with increased risk of serious respiratory illness and hospitalisation in older adults. While vaccines are now available for RSV, there are currently no licensed vaccines for hMPV or PIV3, highlighting the need for continued research.
The purpose of this Phase 1/2 study is to evaluate the safety and immune response of different doses of the investigational vaccine compared with placebo in adults aged 60 to 85 years.
You may be eligible if:
If eligible, you will take part in the study for up to 24 months, including screening, vaccination and follow-up. The study involves 7 clinic visits and 4 phone calls. Clinic visits will take place during clinic business hours of 9-5 weekdays.
Participants will receive one vaccination of either the investigational vaccine or a placebo. Participants are randomly assigned to study groups, and neither you nor the study team will know which treatment you receive.
Throughout the study, doctors and site staff or clinical team will closely monitor your health through regular check-ups and testing. Study assessments may include physical examinations, vital signs, blood tests, and review of any side effects following vaccination.
Before enrolling, the study doctor and clinical team will explain the study in detail, including findings from previous research, potential risks and benefits, and what participation involves.
Eligible participants will receive $2200 reimbursement for study-related time and travel.